Russian Federation vs Saudi Arabia: Share of E. coli infections resistant to cephalosporins
Russian Federation
58.5%
in 2021
Saudi Arabia
52.8%
in 2022
Russian Federation rank
13th
Saudi Arabia rank
15th
Share of E. coli infections resistant to cephalosporins over time
- Russian Federation
- Saudi Arabia
How they compare
Russian Federation currently reports 58.5% against 52.8% in Saudi Arabia, a difference of 5.7%.
That makes Russian Federation's figure about 1.1 times Saudi Arabia's.
Across all 5 years both countries report, Russian Federation has been ahead every year.
Russian Federation ranks 13th and Saudi Arabia ranks 15th of 46 countries.
Russian Federation has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Russian Federation | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 66.0% | 54.3% | 11.7% | Russian Federation |
| 2020s | 65.8% | 55.6% | 10.2% | Russian Federation |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of e. coli infections resistant to cephalosporins, Russian Federation or Saudi Arabia?
- Russian Federation, at 58.5% against 52.8% in Saudi Arabia as of 2021.
- What is the difference in share of e. coli infections resistant to cephalosporins between Russian Federation and Saudi Arabia?
- 5.7%, with Russian Federation ahead.
- How many years of comparable data are there for Russian Federation and Saudi Arabia?
- 5 years are reported by both, from 2017 to 2021.
- How do Russian Federation and Saudi Arabia rank globally for share of e. coli infections resistant to cephalosporins?
- Russian Federation ranks 13th and Saudi Arabia ranks 15th of 46 countries.
- Where does this data come from?
- World Health Organization – processed by Our World in Data, published as Share of E. coli infections resistant to cephalosporins. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%).